BridgeBio Pharma, Inc. (BBIO) is held by 3 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 4 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $836.5K sold). 1 member of Congress reported 4 purchases vs 1 sale. Latest close $78.01 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Oct 30, 2026 · Congress to Nov 16, 2026.
Viking Global Investors · Axiom Investors · Polen Capital Management — 3 tracked funds hold BBIO. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 3 sales ($836.5K). Insider trading 1 member of Congress reported buying (4 purchases vs 1 sale). Latest buy: Nov 2, 2026. Politician trading
Tesla, Inc. (TSLA) · Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Viking Global Investors | 2.11% | 9,949,219 | TRIMMED (-16.0%) Q3 filed Nov 16 |
| Axiom Investors | 0.05% | 76,148 | TRIMMED (-61.9%) Q3 filed Nov 12 |
| Polen Capital Management | <0.01% | 4,002 | TRIMMED (-91.3%) Q3 filed Nov 13 |
| Deep Track Capital | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +3.1% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 477 of 8,857 filers |
| Long-only filers among them | 471 |
| Change vs 2026 Q1 | +25 net · 446 entered · 421 exited |
| Shares reported, all filers | 193,538,376 |
| Reported value, all filers | $15.0B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $502.1M |
| Net income · FY2025 | $-732.9M |
| Total assets · FY2025 | $936.0M |
| Shares outstanding | 194,800,782 |
| Market cap (at latest close) | $15.2B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 22, 2026.
| Shares short · Oct 15, 2026 | 19,997,556 |
| Share of shares outstanding | 10.27% |
| Days to cover | 7.68 |
Shares short at recent settlements — Jul 31, 2026: 23.3M · Aug 14, 2026: 23.3M · Aug 31, 2026: 21.8M · Sep 15, 2026: 21.5M · Sep 30, 2026: 19.7M · Oct 15, 2026: 20.0M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 22, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 22, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 3 sales by 2 insiders ($836.5K).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | Apuli Maricel | Chief Accounting Officer | Sell | 2,000 | $72.85 | $145.7K | SEC filing |
| Sep 17, 2026 | Kumar Neil | Chief Executive Officer | Sell | 8,721 | $69.01 | $601.9K | SEC filing |
| Sep 17, 2026 | Kumar Neil | Chief Executive Officer | Sell | 1,279 | $69.57 | $89.0K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019 | Director, Officer | 30,000 | $2.5M | Aug 19, 2026 | SEC filing |
| Aug 18, 2026 | NEIL KUMAR | Director, Officer | 34,980 | $2.8M | Aug 18, 2026 | SEC filing |
| Aug 17, 2026 | RANDAL SCOTT | Director | 21,501 | $1.7M | Aug 17, 2026 | SEC filing |
| Jul 9, 2026 | JENNIFER COOK | Director | 148,589 | $13.2M | Jul 9, 2026 | SEC filing |
| Jul 9, 2026 | ANDREA ELLIS | Director | 17,167 | $1.4M | Jul 9, 2026 | SEC filing |
| Jun 24, 2026 | RANDAL SCOTT | Director | 2,196 | $150.7K | Jun 24, 2026 | SEC filing |
| Jun 24, 2026 | JENNIFER COOK | Director | 37,167 | $2.6M | Jun 24, 2026 | SEC filing |
| Jun 23, 2026 | JENNIFER COOK | Director | 2,196 | $150.6K | Jun 23, 2026 | SEC filing |
| Jun 23, 2026 | HANNAH A VALANTINE | Director | 2,196 | $150.6K | Jun 23, 2026 | SEC filing |
| Jun 22, 2026 | HANNAH A VALANTINE | Director | 2,808 | $190.9K | Jun 22, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Aug 17, 2026 | SCHEDULE 13D/A | -7.4% (close Aug 18, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Aug 18, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | KKR Genetic Disorder L.P. | SC 13D/A | 8,260,971 | 4.2% | Aug 13, 2026 | SEC filing |
| Aug 3, 2026 | Farallon Capital Management, L.L.C. | SC 13G/A | 10,743,063 | 5.5% | Jun 30, 2026 | SEC filing |
| Jul 27, 2026 | BlackRock, Inc. | SC 13G/A | 9,733,762 | 5.0% | Jun 30, 2026 | SEC filing |
| Jul 10, 2026 | VIKING GLOBAL INVESTORS LP | SC 13D/A | 9,792,219 | 5.0% | Jul 9, 2026 | SEC filing |
| May 29, 2026 | Farallon Capital Partners, L.P. | SC 13G | 728,238 | 0.4% | May 22, 2026 | SEC filing |
| May 15, 2026 | JANUS HENDERSON GROUP PLC | SC 13G/A | 13,179,013 | 6.8% | Mar 31, 2026 | SEC filing |
| Apr 16, 2026 | SC 13G/A | — | — | — | SEC filing | |
| Apr 2, 2026 | VIKING GLOBAL INVESTORS LP | SC 13D/A | 11,842,434 | 6.1% | Mar 31, 2026 | SEC filing |
| Mar 26, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 17, 2026 | JANUS HENDERSON GROUP PLC | SC 13G | 11,000,457 | 5.7% | Dec 31, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
1 member of Congress reported buying (4 purchases vs 1 sale). Bought by Democrats. Latest buy: Nov 2, 2026.
Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.
Recent activity by member
| Member | Chamber | Party | Buys | Sells | Latest | Amount range |
|---|---|---|---|---|---|---|
| Cisneros, Gilbert | House | D | 4 | 1 | Nov 2, 2026 | $1,001 - $15,000 |
Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 31 Lobbying Disclosure Act filings named this company as client, 2023–2026; most common issues: Pharmacy (23), Health Issues (8), Medicare/Medicaid (7).
Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Politicians
· Bought by Members — Last 6 months: bought by a member of the U.S. Congress
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
· Excess Accruals (Sloan) — Sloan accruals ratio beyond ±25%
Key figures
· Bought by Members — Members buying: 1 · Buy txns: 4 · Sell txns: 1 · Latest buy: Nov 2, 2026
· Distress Risk (Altman Z″) — Z″-Score: -14.22 · Working capital / assets: 0.54 · Retained earnings / assets: -4.08 · EBIT / assets: -0.56 · Equity / liabilities: -0.69
· Excess Accruals (Sloan) — Accruals ratio: -28.1% · Net income: $-732.9M · Operating cash flow: $-445.9M · Investing cash flow: $-24.5M
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2021 Q4, ranked #8 of 50.
· Politician BEST — appeared in 1 of the last 20 quarterly lists; latest 2026 Q2, ranked #42 of 50.
Also held by the tracked funds that hold BBIO — ranked by lift, the co-holding pattern described in Methodology: Tesla, Inc. (TSLA) · Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT).
7 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Oct 29, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 13, 2026 | 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 31, 2026 | 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Tesla, Inc. (TSLA) · Track Record: how the signals scored · Practice timing on BBIO
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.